Cargando…

The use of ustekinumab and guselkumab in a pediatric psoriasis patient with active hepatitis B infection

Detalles Bibliográficos
Autores principales:	Song, Eingun James, Whitman, Patrick, Samsel, Jonmichael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806953/ https://www.ncbi.nlm.nih.gov/pubmed/33490344 http://dx.doi.org/10.1016/j.jdcr.2020.12.006

Ejemplares similares

Guselkumab More Effectively Neutralizes Psoriasis-Associated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab
por: Campbell, Kim, et al.
Publicado: (2023)

Guselkumab for the treatment of severe refractory psoriasis in a pediatric patient
por: Kim, Sa Rang, et al.
Publicado: (2019)

Eczematous eruption after guselkumab treatment for psoriasis
por: Reyn, Birgit, et al.
Publicado: (2019)

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab
por: Bartholomew, Erin, et al.
Publicado: (2023)

Guselkumab for plaque psoriasis
Publicado: (2019)

Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate‐to‐severe plaque psoriasis: the COMPASS analysis
por: Diels, J., et al.
Publicado: (2020)

Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis
por: Olabi, Bayanne, et al.
Publicado: (2020)

Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis
por: Lynch, Maeve, et al.
Publicado: (2017)

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
por: Hampton, Philip, et al.
Publicado: (2021)

Guselkumab for the treatment of psoriasis – evidence to date
por: Nogueira, Miguel, et al.
Publicado: (2019)

Successful treatment of psoriasis with risankizumab in a patient with telangiectasia macularis eruptiva perstans
por: Barber, Cara, et al.
Publicado: (2022)

New-onset systemic lupus erythematous in a patient receiving risankizumab for psoriasis
por: Barber, Cara, et al.
Publicado: (2022)

Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab
por: Chiang, Cheng-Ying, et al.
Publicado: (2021)

Urticarial Reaction to Ustekinumab During the Treatment of Plaque Psoriasis in a Hepatitis C-Positive Patient
por: Chu, Christopher H., et al.
Publicado: (2017)

Ustekinumab-induced amelioration of both palmoplantar psoriasis and psoriatic glossitis
por: Tonini, Annalisa, et al.
Publicado: (2019)

Arthritis Interception in Patients with Psoriasis Treated with Guselkumab
por: Zabotti, Alen, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center
por: Jung, Seung-Won, et al.
Publicado: (2022)

A Case of the Safety and Efficacy of Guselkumab in Psoriasis with Alcoholic Liver Cirrhosis
por: Nam, Hyun Min, et al.
Publicado: (2021)

The use of interleukin 23 inhibitors in patients with chronic hepatitis B infection: A case series
por: Ch’en, Peter Yi, et al.
Publicado: (2022)

The use of ustekinumab in a patient with severe psoriasis and positive HBV serology()
por: Steglich, Raquel Bissacotti, et al.
Publicado: (2014)

Recapturing adequate control of psoriasis by additional immunosuppressive agents alongside ustekinumab
por: Jayasekera, Prativa S., et al.
Publicado: (2016)

Paradoxical Flare of Psoriasis after Ustekinumab Therapy
por: Lee, Ho Yeol, et al.
Publicado: (2017)

Ustekinumab: differential use in psoriasis
por: Uhlenhake, Elizabeth E, et al.
Publicado: (2011)

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
por: Matsumoto, Satohiro, et al.
Publicado: (2018)

Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab
por: Petty, Amy J., et al.
Publicado: (2020)

Plaque psoriasis and morphea in a patient on ustekinumab: A case report
por: Cirone, Katrina, et al.
Publicado: (2023)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Nakamura, Mio, et al.
Publicado: (2017)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
por: Light, Jeremy G, et al.
Publicado: (2021)

Ustekinumab in the therapy of chronic plaque psoriasis
por: O’Neill, Jenna L, et al.
Publicado: (2009)

Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015)

Ustekinumab-induced autoimmune hepatitis: a case report
por: Samah, Ali Said, et al.
Publicado: (2023)

Modified dose of guselkumab for treatment of pyoderma gangrenosum
por: Reese, Ashley M., et al.
Publicado: (2022)

Erythema multiforme after initiation of anti interleukin-12/23 (ustekinumab) treatment for plaque psoriasis
por: Burlando, Martina, et al.
Publicado: (2020)

Guselkumab‐associated bullous pemphigoid in a psoriasis patient: A case report and review of the literature
por: Burlando, Martina, et al.
Publicado: (2021)

Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis
por: MÄLKÖNEN, Tarja, et al.
Publicado: (2022)

Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
por: Yang, Eric J, et al.
Publicado: (2019)

Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
por: Mastorino, Luca, et al.
Publicado: (2022)

Severe Nail Fold Psoriasis Extending from Nail Psoriasis Resolved with Ustekinumab: Suggestion of a Cytokine Overflow Theory in the Nail Unit
por: Byun, Sang Young, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_eifslcsnv4lnltaivee9kffn8m